Palbociclib and Letrozole in Advanced Breast Cancer
The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
BACKGROUND: A phase 2 study showed that progression-free survival was longer with palbociclib plus letrozole than with letrozole alone in the initial treatment of postmenopausal women with estrogen-receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer. We performed a phase 3 study that was designed to confirm and expand the efficacy and safety data for palbociclib plus letrozole for this indication. METHODS: In this double-blind study, we randomly assigned, in a 2:1 ratio, 666 postmenopausal women with ER-positive, HER2-negative breast cancer, who had not had prior treatment for advanced disease, to receive palbociclib plus letrozole or placebo plus letrozole. The primary end point was progression-free survival, as assessed by the investigators; secondary end points were overall survival, objective response, clinical benefit response, patient-reported outcomes, pharmacokinetic effects, and safety. RESULTS: The median progression-free survival was 24.8 months (95% confidence interval [CI], 22.1 to not estimable) in the palbociclib-letrozole group, as compared with 14.5 months (95% CI, 12.9 to 17.1) in the placebo-letrozole group (hazard ratio for disease progression or death, 0.58; 95% CI, 0.46 to 0.72; P<0.001). The most common grade 3 or 4 adverse events were neutropenia (occurring in 66.4% of the patients in the palbociclib-letrozole group vs. 1.4% in the placebo-letrozole group), leukopenia (24.8% vs. 0%), anemia (5.4% vs. 1.8%), and fatigue (1.8% vs. 0.5%). Febrile neutropenia was reported in 1.8% of patients in the palbociclib-letrozole group and in none of the patients in the placebo-letrozole group. Permanent discontinuation of any study treatment as a result of adverse events occurred in 43 patients (9.7%) in the palbociclib-letrozole group and in 13 patients (5.9%) in the placebo-letrozole group. CONCLUSIONS: Among patients with previously untreated ER-positive, HER2-negative advanced breast cancer, palbociclib combined with letrozole resulted in significantly longer progression-free survival than that with letrozole alone, although the rates of myelotoxic effects were higher with palbociclib-letrozole. (Funded by Pfizer; PALOMA-2 ClinicalTrials.gov number, NCT01740427 .).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The last 2 years have seen the establishment of cyclin-dependent kinase (CDK)4/6 inhibitors combined with endocrine therapy (ET) as the standard of care for ER-positive/HER2-negative ABC”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [43]
In the citing paper
“substantial PFS benefit and good toxicity profile.36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [43]
In the citing paper
“These agents can be combined with an aromatase inhibitor (AI) or fulvestrant, and are effective in de novo or recurrent ABC, in first or second line, in cases of primary or secondary resistance, in postmenopausal and premenopausal women (the latter with ovarian function suppression/ablation), and in men (preferably with a luteinising hormone-releasing hormone agonist).”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [43]
In the citing paper
“Although palbociclib was the first CDK4/6 inhibitor to demonstrate clinical efficacy (Finn et al., 2016), there are two others that soon followed.”
From CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought (2018) · cites this paper as Finn et al., 2016
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Finn, R. S., Crown, J. P., Lang, I., Boer, K., Bondarenko, I. M., Kulyk, S. O., Ettl, J., Patel, R., Pinter, T., Schmidt, M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71159-3 · Cited by 1,900
Self-citationCristofanilli, M., Turner, N. C., Bondarenko, I., Ro, J., Im, S.-A., Masuda, N., Colleoni, M., DeMichele, A., Loi, S., Verma, S., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00613-0 · Cited by 1,827
Self-citationFinn, R. S., Dering, J., Conklin, D., Kalous, O., Cohen, D. J., Desai, A. J., Ginther, C., Atefi, M., Chen, I., Fowst, C., et al. (2009) · Breast Cancer Research · doi:10.1186/bcr2419 · Cited by 1,398
Self-citationFry, D. W., Harvey, P. J., Keller, P. R., Elliott, W. L., Meade, M., Trachet, E., Albassam, M., Zheng, X., Leopold, W. R., Pryer, N. K., et al. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1427.3.11 · Cited by 1,236
Y. Maximov, P., M. Lee, T., & Craig Jordan, V. (2013) · Current Clinical Pharmacology · doi:10.2174/1574884711308020006 · Cited by 376
Beaver, J. A., Amiri-Kordestani, L., Charlab, R., Chen, W., Palmby, T., Tilley, A., Zirkelbach, J. F., Yu, J., Liu, Q., Zhao, L., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1185 · Cited by 373
Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers
Finn, R. S., Aleshin, A., & Slamon, D. J. (2016) · Breast Cancer Research · doi:10.1186/s13058-015-0661-5 · Cited by 368
Self-citationMartín, M., Loibl, S., von Minckwitz, G., Morales, S., Martinez, N., Guerrero, A., Anton, A., Aktas, B., Schoenegg, W., Muñoz, M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.2388 · Cited by 131
Dickler, M. N., Barry, W. T., Cirrincione, C., Ellis, M. J., Moynahan, M. E., Innocenti, F., Hurria, A., Rugo, H. S., Lake, D. E., Hahn, O. M., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.66.1595 · Cited by 128
Self-citation
Cited by
Items 201–300 of 1,002
Jin, H., Du, W., Huang, W., Yan, J., Tang, Q., Chen, Y., & Zou, Z. (2021) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2021.08.005 · Cited by 122
O’Brien, N. A., Conklin, D. F., Beckmann, R. P., Luo, T., Chau, K., Thomas, J. D., Nulty, A. M., Marchal, C. C., Kalous, O., von Euw, E., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0290 · Cited by 116
“The cyclin dependent kinases 4 and 6 (CDK4/6) are key regulators of the G1 to S-phase restriction checkpoint and pharmacologically targeting these proteins in combination with hormonal blockade has been shown to provide significant therapeutic benefit to patients with advanced ER+/HER2- breast cancer (13-15).”
BackgroundSelf-citationSubhan, M. A., Parveen, F., Shah, H., Yalamarty, S. S. K., Ataide, J. A., & Torchilin, V. P. (2023) · Cancers · doi:10.3390/cancers15082204 · Cited by 118
Kalinsky, K. M., Bianchini, G., Hamilton, E. P., Graff, S. L., Park, K. H., Jeselsohn, R. M., Demırcı, U., Martín, M., Layman, R. M., Hurvitz, S. A., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco-24-02086 · Cited by 152
Zhang, Q. Y., Sun, T., Yin, Y. M., Li, H. P., Yan, M., Tong, Z. S., Oppermann, C. P., Liu, Y. P., Costa, R. L. D. P., Li, M., et al. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920963925 · Cited by 112
Nexus between PI3K/AKT and Estrogen Receptor Signaling in Breast Cancer
Khatpe, A. S., Adebayo, A. K., Herodotou, C., Kumar, B., & Nakshatri, H. (2021) · Cancers · doi:10.3390/cancers13030369 · Cited by 117
“Palbociclib and Letrozole combination (PALOMA-2 trial) [78,79] 2.”
BackgroundCretella, D., Ravelli, A., Fumarola, C., La Monica, S., Digiacomo, G., Cavazzoni, A., Alfieri, R., Biondi, A., Generali, D., Bonelli, M., et al. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0741-3 · Cited by 107
“Palbociclib granted accelerated approval in 2015 for the treatment of ER-positive, HER2-negative advanced BC in association with letrozole [10], and in combin-”
CDKN2A loss-of-function predicts immunotherapy resistance in non-small cell lung cancer
Gutiontov, S. I., Turchan, W. T., Spurr, L. F., Rouhani, S. J., Chervin, C. S., Steinhardt, G., Lager, A. M., Wanjari, P., Malik, R., Connell, P. P., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-99524-1 · Cited by 116
Dieras, V. C., Rugo, H. S., Schnell, P., Gelmon, K. A., Cristofanilli, M., Loi, S., Colleoni, M. A., Lu, D. R., Mori, A., Gauthier, E. R., et al. (2018) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djy109 · Cited by 106
“worth noting, however, that QoL can be maintained in patients treated with palbociclib plus endocrine therapy (23,24) through the use of appropriate supportive care and dose modifications as needed to manage AEs such as neutropenia, the most common AE associated with palbociclib (3).”
BackgroundSelf-citationSchettini, F., Giudici, F., Giuliano, M., Cristofanilli, M., Arpino, G., Mastro, L. D., Puglisi, F., Placido, S. D., Paris, I., Placido, P. D., et al. (2020) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djaa071 · Cited by 111
Asghar, U. S., Kanani, R., Roylance, R. R., & Mittnacht, S. (2022) · JCO Precision Oncology · doi:10.1200/po.21.00002 · Cited by 119
Zhu, X., Chen, L., Huang, B., Li, X., Yang, L., Hu, X., Jiang, Y., Shao, Z., & Wang, Z. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01930-w · Cited by 96
“neutropenia, leukopenia, anaemia and fatigue occurred at a higher frequency [62].”
BackgroundLlombart‐Cussac, A., Pérez-García, J. M., Bellet, M., Dalenc, F., Gil‐Gil, M., Ruíz‐Borrego, M., Gavilá, J., Sampayo-Cordero, M., Aguirre, E., Schmid, P., et al. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2021.4301 · Cited by 110
Yu, J., Mu, Q., Fung, M., Xu, X., Zhu, L., & Ho, R. J. Y. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108108 · Cited by 114
Whittle, J. R., Vaillant, F., Surgenor, E., Policheni, A. N., Giner, G., Capaldo, B. D., Chen, H.-R., Liu, H. K., Dekkers, J. F., Sachs, N., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1872 · Cited by 102
Chohan, T. A., Qayyum, A., Rehman, K., Tariq, M., & Akash, M. S. H. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.08.116 · Cited by 112
Niu, Y., Xu, J., & Sun, T. (2019) · Journal of Cancer · doi:10.7150/jca.32628 · Cited by 110
Lu, Y., Mahidin, E. I. B. M., Azim, H. A., Eralp, Y., Yap, Y. S., Im, S., Rihani, J., Gökmen, E., Bastawisy, A. E., Karadurmuş, N., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.24.00144 · Cited by 111
Self-citationTurner, N. C., Finn, R. S., Martín, M., Im, S., DeMichele, A. M., Ettl, J., Dieras, V. C., Moulder, S., Lipatov, O. N., Colleoni, M. A., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdx797 · Cited by 100
“patients with TFI 36 months [13, 17]; the difference in findings between the studies is potentially explained by the different durations of follow-up.”
BackgroundMethodResultSelf-citationMayer, I. A., Prat, A., Egle, D., Blau, S., Fidalgo, J. A. P., Gnant, M., Fasching, P. A., Colleoni, M., Wolff, A. C., Winer, E. P., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3160 · Cited by 97
“org Clin Cancer Res; 25(10) May 15, 2019 2979”
BackgroundInfluentialPathway‐level mutational signatures predict breast cancer outcomes and reveal therapeutic targets
Posta, M., & Győrffy, B. (2025) · British Journal of Pharmacology · doi:10.1111/bph.70215 · Cited by 120
Colón‐Otero, G., Zanfagnin, V., Hou, X., Foster, N. R., Asmus, E. J., Hendrickson, A. W., Jatoi, A., Block, M. S., Langstraat, C., Glaser, G. E., et al. (2020) · ESMO Open · doi:10.1136/esmoopen-2020-000926 · Cited by 101
Burris, H. A., Chan, A., Bardia, A., Beck, J. T., Sohn, J., Neven, P., Tripathy, D., Im, S., Chia, S., Esteva, F. J., et al. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01415-9 · Cited by 105
Self-citationMiglietta, F., Bottosso, M., Griguolo, G., Dieci, M. V., & Guarneri, V. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100409 · Cited by 109
Chemoresistance and Metastasis in Breast Cancer Molecular Mechanisms and Novel Clinical Strategies
Cao, J., Zhang, M., Wang, B., Zhang, L., Zhou, F., & Fang, M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.658552 · Cited by 114
“Moreover, the combination of Palbociclib and Letrozole resulted in significantly longer PFS than monotherapy among patients with advanced BRCA (96).”
BackgroundClinical Implications of ESR1 Mutations in Hormone Receptor-Positive Advanced Breast Cancer
Reinert, T., Saad, E. D., Barrios, C. H., & Bines, J. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00026 · Cited by 107
“Palbociclib is currently used in routine clinical practice in the USA both in first- and second-line setting following its approval by the Food and Drug Administration based on three randomized clinical trials (PALOMA 1, 2, and 3) (40, 41, 45) that demonstrated a significant benefit in terms of PFS and clinical benefi…”
MethodYeruva, S. L. H., Zhao, F., Miller, K. D., Tevaarwerk, A. J., Wagner, L. I., Gray, R. J., Sparano, J. A., & Connolly, R. M. (2018) · npj Breast Cancer · doi:10.1038/s41523-017-0053-3 · Cited by 93
“More recently, the cyclin-dependent kinase (CDK) 4/6 inhibitor palbociclib and letrozole combination was approved for patients with HR-positive advanced breast cancer as a front-line therapy after a significant improvement in PFS was observed in both the PALOMA-1 and PALOMA-2 trials for the combination versus letrozol…”
MethodTargeting cyclin-dependent kinases for the treatment of pulmonary arterial hypertension
Weiß, A., Neubauer, M. C., Yerabolu, D., Kojonazarov, B. K., Schlueter, B. C., Neubert, L., Jonigk, D. D., Baal, N., Ruppert, C., Dorfmüller, P., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10135-x · Cited by 100
Pancholi, S., Ribas, R., Simigdala, N., Schuster, E. F., Nikitorowicz-Buniak, J., Ressa, A., Gao, Q., Leal, M. F., Bhamra, A., Thornhill, A. M., et al. (2020) · Oncogene · doi:10.1038/s41388-020-1284-6 · Cited by 98
Larionov, A. A. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00089 · Cited by 102
“org April 2018 | Volume 8 | Article 89 A significant progress has been made over the recent years in the treatment of metastatic ER-positive HER2-negative breast cancer: fulvestrant (500 mg) has been promoted to first line metastatic hormonal treatment (73) and CDK4/6 inhibitors have been established as a standard add…”
BackgroundLloyd, M. R., Spring, L. M., Bardia, A., & Wander, S. A. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2947 · Cited by 101
Can EGFR be a therapeutic target in breast cancer?
Li, X., Zhao, L., Chen, C., Nie, J., & Jiao, B. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188789 · Cited by 110
Revolutionizing cancer care strategies: immunotherapy, gene therapy, and molecular targeted therapy
Zafar, A., Khan, M. J., Abu, J., & Naeem, A. (2024) · Molecular Biology Reports · doi:10.1007/s11033-023-09096-8 · Cited by 106
“However, it’s essential to note that the combination treatment does come with pronounced myelosuppression [93].”
BackgroundVerma, S., O’Shaughnessy, J., Burris, H. A., Campone, M., Alba, E., Chandiwana, D., Dalal, A. A., Sutradhar, S., Monaco, M., & Janni, W. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-4769-z · Cited by 100
“In general, CDK4/6 inhibitor-based regimens are associated with predictable and manageable safety profiles, with myelosuppression observed most commonly [4, 6, 8].”
BackgroundAl Baghdadi, T., Halabi, S., Garrett-Mayer, E., Mangat, P. K., Ahn, E. R., Sahai, V., Alvarez, R. H., Kim, E. S., Yost, K. J., Rygiel, A. L., et al. (2019) · JCO Precision Oncology · doi:10.1200/po.19.00124 · Cited by 94
“Palbociclib is approved for the treatment of patients with advanced hormone receptor–positive, HER2-negative breast cancer in combination with an aromatase inhibitor or fulvestrant.(21,22) Palbociclib showed promising activity in patients with liposarcoma(23) and CDKN2A-mutated non–smallcell lung cancer.”
BackgroundXi, J., Oza, A., Thomas, S. N., Ademuyiwa, F. O., Weilbaecher, K. N., Suresh, R., Bose, R., Cherian, M. A., Hernandez-Aya, L. F., Frith, A. E., et al. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.7094 · Cited by 95
Epidemiology of De Novo Metastatic Breast Cancer
Daily, K. C., Douglas, E. H., Romitti, P. A., & Thomas, A. (2021) · Clinical Breast Cancer · doi:10.1016/j.clbc.2021.01.017 · Cited by 94
Griffiths, J. I., Chen, J., Cosgrove, P. A., O’Dea, A. P., Sharma, P., Ma, C. X., Trivedi, M. S., Kalinsky, K. M., Wisinski, K. B., O'Regan, R. M., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00215-7 · Cited by 104
Konstantinopoulos, P. A., Lee, E. K., Xiong, N., Krasner, C. N., Campos, S. M., Kolin, D. L., Liu, J. F., Horowitz, N. S., Wright, A. A., Bouberhan, S., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.00628 · Cited by 102
Meattini, I., Becherini, C., Caini, S., Coles, C. E., Cortés, J., Curigliano, G., de Azambuja, E., Isacke, C. M., Harbeck, N., Kaidar‐Person, O., et al. (2024) · The Lancet Oncology · doi:10.1016/s1470-2045(23)00534-x · Cited by 99
Self-citationInhibiting CDK in Cancer Therapy: Current Evidence and Future Directions
Vijayaraghavan, S., Moulder, S., Keyomarsi, K., & Layman, R. M. (2017) · Targeted Oncology · doi:10.1007/s11523-017-0541-2 · Cited by 99
“3%) had received prior endocrine therapy in the adjuvant setting; however, patients could not have developed disease recurrence while on a non-steroidal AI within the prior 12 months [34].”
BackgroundMethodSelf-citationThe Ongoing Search for Biomarkers of CDK4/6 Inhibitor Responsiveness in Breast Cancer
Schoninger, S., & Blain, S. W. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0253 · Cited by 95
“Subsequent completed trials of palbociclib in breast cancer have only included patients with ER/PRþ, HER2- tumors; thus, there is a sparsity of clinical data to directly support the hypothesis that palbociclib is only active in HRþ tumors without HER2 (6, 7, 28).”
BackgroundMethodTranscription and Translation Inhibitors in Cancer Treatment
Laham-Karam, N., Pinto, G., Poso, A., & Kokkonen, P. (2020) · Frontiers in Chemistry · doi:10.3389/fchem.2020.00276 · Cited by 95
“Palbociclib (Figure 5) is a selective inhibitor of CDK4 and CDK6 and it was the first inhibitor of CDKs that was approved as a cancer therapy in combination with letrozole, an aromatase inhibitor (Lu, 2015; Turner et al., 2015; Finn et al., 2016).”
BackgroundValproic acid as an adjunctive therapeutic agent for the treatment of breast cancer
Heers, H., Stanislaw, J., Harrelson, J. P., & Lee, M. W. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.07.057 · Cited by 96
Dieras, V. C., Harbeck, N., Joy, A. A., Gelmon, K. A., Ettl, J., Verma, S., Lu, D. R., Gauthier, E. R., Schnell, P., Mori, A., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0019 · Cited by 93
“A recent exposureresponse analysis of PALOMA-2 showed that PFS was similar between Asian and non-Asian patients, even though Asian patients had more frequent dose reductions [21].”
BackgroundMethodResultSelf-citationYuan, Y., Lee, J. S., Yost, S. E., Frankel, P. H., Ruel, C., Egelston, C. A., Guo, W., Padam, S., Tang, A., Martínez, N., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.05.035 · Cited by 97
Cell cycle dysregulation in cancer
Glaviano, A., Singh, S. K., Lee, E. H. C., Okina, E., Lam, H. Y., Carbone, D., Reddy, E. P., O’Connor, M. J., Koff, A., Singh, G., et al. (2024) · Pharmacological Reviews · doi:10.1016/j.pharmr.2024.100030 · Cited by 110
The Emerging Role of Cyclin-Dependent Kinases (CDKs) in Pancreatic Ductal Adenocarcinoma
García-Reyes, B., Kretz, A.-L., Ruff, J.-P., von Karstedt, S., Hillenbrand, A., Knippschild, U., Henne‐Bruns, D., & Lemke, J. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19103219 · Cited by 102
“Phase II Advanced breast cancer [250,251] In combination with anastrozole, letrozole”
BackgroundJin, X., Ge, L., Li, D., Shao, Z., Di, G. H., Xu, X., & Jiang, Y. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01210-9 · Cited by 92
The emerging role of molecular pathology in directing the systemic treatment of endometrial cancer
Jamieson, A., Bosse, T., & McAlpine, J. N. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211035959 · Cited by 95
López-González, L., Cendra, A. S., Cendra, C. S., Cervantes, E. D. R., Espinosa, J. C., Pekarek, T., Fraile‐Μartinez, O., Montero, C. G., Rodriguez-Slocker, A. M., Jiménez-Álvarez, L., et al. (2024) · Medicina · doi:10.3390/medicina60010168 · Cited by 107
“Overexpression of cyclin D1 increases cyclin-dependent kinases 4 and 6 (CDK4/6) and stimulates cell division, making this pathway an attractive target in cancer therapy [100–104].”
BackgroundRugo, H. S., Turner, N. C., Finn, R. S., Joy, A. A., Verma, S., Harbeck, N., Masuda, N., Im, S., Huang, X., Kim, S., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.05.017 · Cited by 91
Self-citationSonke, G. S., Hart, L. L., Campone, M., Erdkamp, F., Janni, W., Verma, S., Villanueva, C., Jakobsen, E. H., Alba, E., Wist, E., et al. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4523-y · Cited by 92
“Other CDK4/6 inhibitorbased regimens have also demonstrated efficacy in elderly patients [23, 27], further supporting CDK4/6 inhibitors as a valuable treatment option in elderly patients with HR? advanced breast cancer.”
BackgroundSammons, S. L., Topping, D. L., & Blackwell, K. (2017) · Current Cancer Drug Targets · doi:10.2174/1568009617666170330120452 · Cited by 96
“6% of patients in the PALOMA-2, PALOMA-3, MONALEESA-2, and MONARCH-1 clinical trials, respectively [12-14].”
BackgroundInfluentialA contemporary review of male breast cancer: current evidence and unanswered questions
Leon-Ferre, R. A., Giridhar, K. V., Hieken, T. J., Mutter, R. W., Couch, F. J., Jiménez, R. E., Hawse, J. R., Boughey, J. C., & Ruddy, K. J. (2018) · Cancer and Metastasis Reviews · doi:10.1007/s10555-018-9761-x · Cited by 96
Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer
Sonke, G. S., van Ommen‐Nijhof, A., Wortelboer, N., van der Noort, V., Swinkels, A. C. P., Blommestein, H. M., Páez, C. G., Mol, L., Beeker, A., Beelen, K. J., et al. (2024) · Nature · doi:10.1038/s41586-024-08035-2 · Cited by 105
c-myc regulates the sensitivity of breast cancer cells to palbociclib via c-myc/miR-29b-3p/CDK6 axis
Ji, W., Zhang, W., Wang, X., Shi, Y., Yang, F., Xie, H., Zhou, W., Wang, S., & Guan, X. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-02980-2 · Cited by 94
Alves, C. L., Ehmsen, S., Terp, M. G., Portman, N., Tuttolomondo, M., Gammelgaard, O. L., Hundebøl, M. F., Kaminska, K. K., Johansen, L. E., Bak, M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25422-9 · Cited by 97
Combination of palbociclib and radiotherapy for glioblastoma
Whittaker, S. P., Madani, D., Joshi, S. M., Chung, S. A., Johns, T. G., Day, B. W., Khasraw, M., & McDonald, K. L. (2017) · Cell Death Discovery · doi:10.1038/cddiscovery.2017.33 · Cited by 94
Min, A., Kim, J. E., Kim, Y., Lim, J. M., Kim, S., Kim, J. W., Lee, K.-H., Kim, T., Oh, D., Bang, Y., et al. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.04.037 · Cited by 99
Self-citationThe oligometastatic spectrum in the era of improved detection and modern systemic therapy
Katipally, R. R., Pitroda, S. P., Juloori, A., Chmura, S. J., & Weichselbaum, R. R. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00655-9 · Cited by 94
Glaviano, A., Wander, S. A., Baird, R. D., Yap, K. C.-Y., Lam, H. Y., Toi, M., Carbone, D., Geoerger, B., Serra, V., Jones, R. H., et al. (2024) · Drug Resistance Updates · doi:10.1016/j.drup.2024.101103 · Cited by 96
“Though small-molecule CDK4/6i have shown significant clinical benefit, treatment failure and eventual resistance still represent major obstacles for HR + BC patients (Finn et A. Glaviano et al. (Goetz et al., 2020a).”
Self-citationPI3K/AKT/mTOR inhibitors for hormone receptor-positive advanced breast cancer
Hao, C., Wei, Y., Meng, W., Zhang, J., & Yang, X. (2024) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2024.102861 · Cited by 100
Breast cancer treatment-induced cardiotoxicity
Martel, S., Maurer, C., Lambertini, M., Ponde, N. F., & de Azambuja, E. (2017) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1351541 · Cited by 89
Mechanisms of Resistance to CDK4/6 Inhibitors in Breast Cancer and Potential Biomarkers of Response
Guarducci, C., Bonechi, M., Boccalini, G., Benelli, M., Risi, E., Leo, A. D., Malorni, L., & Migliaccio, I. (2017) · Breast Care · doi:10.1159/000484167 · Cited by 91
Breast Cancer Brain Metastasis—Overview of Disease State, Treatment Options and Future Perspectives
Watase, C., Shiino, S., Shimoi, T., Noguchi, E., Kaneda, T., Yamamoto, Y., Yonemori, K., Takayama, S., & Suto, A. (2021) · Cancers · doi:10.3390/cancers13051078 · Cited by 88
Endothelial cell cycle state determines propensity for arterial-venous fate
Chavkin, N. W., Genet, G., Poulet, M., Jeffery, E. D., Marziano, C., Genet, N., Vasavada, H. H., Nelson, E. A., Acharya, B. R., Kour, A., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33324-7 · Cited by 94
Long, F., He, Y., Fu, H., Li, Y., Bao, X., Wang, Q., Wang, Y., Xie, C., & Lou, L. (2019) · Cancer Science · doi:10.1111/cas.13957 · Cited by 87
Neven, P., Fasching, P. A., Chia, S., Jerusalem, G., De Laurentiis, M., Im, S.-A., Petrakova, K., Bianchi, G. V., Martín, M., Nusch, A., et al. (2023) · Breast Cancer Research · doi:10.1186/s13058-023-01701-9 · Cited by 83
“All three approved CDK4/6is (ribociclib, palbociclib, and abemaciclib) have demonstrated a significant progression-free survival (PFS) benefit compared with ET alone when used in the first-line setting [4–8].”
MethodSelf-citationDetection of Activating Estrogen Receptor Gene ( ESR1 ) Mutations in Single Circulating Tumor Cells
Paolillo, C., Mu, Z., Rossi, G., Schiewer, M. J., Nguyen, T., Austin, L., Capoluongo, E., Knudsen, K. E., Cristofanilli, M., & Fortina, P. M. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1173 · Cited by 85
“Instead, she benefited from the prompt switch to a combined therapy of palbociclib and fulvestrant, a highly effective regimen evaluated in the prospective, randomized, phase III study PALOMA-3, whose benefit appears irrespective of common genomic abnormalities such as ESR1 and PI3KCA (38, 39).”
BackgroundRoncato, R., Angelini, J., Pani, A., Cecchin, E., Bianchi, A. S., Siena, S., Mattia, E. D., Scaglione, F., & Toffoli, G. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176350 · Cited by 85
Li, J., Huo, X., Zhao, F., Ren, D., Ahmad, R., Yuan, X., Du, F., & Zhao, J. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.20312 · Cited by 95
Desnoyers, A., Nadler, M. B., Kumar, V., Saleh, R., & Amir, E. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102086 · Cited by 89
Solís, M. C., Gil-Torralvo, A., Castilla, M. Á., Dominguez-Cejudo, M. A., Falcón, A., Benavent, M., Molina‐Pinelo, S., Ruíz-Borrego, M., & Bofill, J. S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24108488 · Cited by 87
“3%), MONARCH2 (55%), and MONARCH 3 (52%) [10,15,16,38,39].”
ResultInfluentialPrecision therapeutics and emerging strategies for HR-positive metastatic breast cancer
Lloyd, M. R., Jhaveri, K. L., Kalinsky, K. M., Bardia, A., & Wander, S. A. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00935-6 · Cited by 97
“…first-line therapy in combination with an anti-oestrogen backbone for patients with metastatic HR + , HER2 − breast cancer; the MONALEESA-2/3/7 trials (ribociclib) 81–83 , MONARCH-3 (abemaciclib) 84 and PALOMA-2 (palbociclib) 85 all demonstrated a similar magnitude of PFS benefit in this setting.”
Im, S., Mukai, H., Park, I. H., Masuda, N., Shimizu, C., Kim, S.-B., Im, Y., Ohtani, S., Bartlett, C. H., Lu, D. R., et al. (2019) · Journal of Global Oncology · doi:10.1200/jgo.18.00173 · Cited by 95
“The amount of improvement in clinical benefit response with palbociclib was similar in Asians and non-Asians and in the ITT population (Table 2).(9) At the time of this analysis, survival data were not yet mature.”
BackgroundMethodResultInfluentialSelf-citationAdvances in Targeted Therapies for Triple-Negative Breast Cancer
McCann, K. E., Hurvitz, S. A., & McAndrew, N. P. (2019) · Drugs · doi:10.1007/s40265-019-01155-4 · Cited by 90
Venous thromboembolism in breast cancer patients receiving cyclin‐dependent kinase inhibitors
Gervaso, L., Montero, A. J., Jia, X., & Khorana, A. A. (2019) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14630 · Cited by 86
Wander, S. A., Han, H. S., Zangardi, M. L., Niemierko, A., Mariotti, V., Kim, L. S., Xi, J., Pandey, A., Dunne, S., Nasrazadani, A., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.7662 · Cited by 88
“this study, because (1) no advantage was noted for patients who received anovel antiestrogenpartnerwith abemaciclib, (2) many patients had prior disease progression onmultiple hormonal agents, and (3) a subgroup of patients received abemaciclib monotherapy with durable clinical benefit.”
ResultCoppola, C., Rienzo, A., Piscopo, G., Barbieri, A., Arra, C., & Maurea, N. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.11.009 · Cited by 94
“The efficacy and safety of this drug was investigated in the PALOMA-1 (phase II) and PALOMA-2 (phase III) trials, where women with advanced or metastatic breast cancer, ERpositive and HER2-negative, were treated with palbocinib in combination with an aromatase inhibitor as initial endocrine-based therapy in postmenopa…”
Xu, B., Hu, X., Li, W., Sun, T., Shen, K., Wang, S., Cheng, Y., Zhang, Q., Cui, S., Tong, Z., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.08.012 · Cited by 88
CDK4/6 inhibitors in breast cancer therapy: Current practice and future opportunities
Lynce, F. C., Shajahan‐Haq, A. N., & Swain, S. M. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.06.008 · Cited by 85
Patel, H., Tao, N., Lee, K.-M., Huerta-Rosario, M., Arlt, H., Mullarkey, T. L., Troy, S. M., Arteaga, C. L., & Bihani, T. (2019) · Breast Cancer Research · doi:10.1186/s13058-019-1230-0 · Cited by 85
Lin, X., Dinglin, X.-X., Cao, S., Zheng, S., Wu, C., Chen, W., Li, Q., Hu, Q., Zheng, F., Wu, Z., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107753 · Cited by 78
Harbeck, N., Bartlett, M., Spurden, D., Hooper, B., Zhan, L., Rosta, E., Cameron, C. G., Mitra, D., & Zhou, A. (2021) · Future Oncology · doi:10.2217/fon-2020-1264 · Cited by 85
Self-citationPetrelli, F., Ghidini, A., Pedersini, R., Cabiddu, M., Borgonovo, K., Parati, M. C., Ghilardi, M., Amoroso, V., Berruti, A., & Barni, S. (2019) · Breast Cancer Research and Treatment · doi:10.1007/s10549-019-05133-y · Cited by 79
Laderian, B., & Fojo, T. (2017) · Seminars in Oncology · doi:10.1053/j.seminoncol.2018.03.006 · Cited by 77
Taylor‐Stokes, G., Mitra, D., Waller, J., Gibson, K., Milligan, G., & Iyer, S. S. (2018) · The Breast · doi:10.1016/j.breast.2018.10.009 · Cited by 77
CDK4/6 inhibitors: a novel strategy for tumor radiosensitization
Yang, Y., Luo, J., Chen, X., Yang, Z., Mei, X., Ma, J., Zhang, Z., Guo, X., & Yu, X. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01693-w · Cited by 82
Fulvestrant in advanced breast cancer: evidence to date and place in therapy
Boér, K. (2017) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834017711097 · Cited by 83
Clinical and molecular aspects of breast cancer: Targets and therapies
Godone, R. L. N., Leitão, G. M., Araújo, N., Castelletti, C. H. M., de Lima-Filho, J. L., & Martins, D. B. G. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.06.066 · Cited by 83
Ballinger, T. J., Meier, J. B., & Jansen, V. M. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00308 · Cited by 82
“The follow up phase III study, PALOMA-2, confirmed these results, leading to regular approval of palbociclib (52).”
ResultDavid, S., Tan, J., Savas, P. S., Bressel, M., Kelly, D., Foroudi, F., Loi, S., & Siva, S. (2019) · The Breast · doi:10.1016/j.breast.2019.10.016 · Cited by 82
“The estimated rate of PFS in the first line setting with CDK4/6 inhibitors in combination with aromatase inhibitors is approximately 50% at 2 years in patients who were untreated or recurred at least 12 months after adjuvant therapy and thus selected for endocrine sensitivity [32,34].”
BackgroundCDK4 phosphorylation status and a linked gene expression profile predict sensitivity to palbociclib
Raspé, E., Coulonval, K., Pita, J. M. G., Paternot, S., Rothé, F., Twyffels, L., Brohée, S., Craciun, L., Larsimont, D., Kruys, V., et al. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201607084 · Cited by 80
“In multiple breast cancer clinical trials (Asghar et al, 2015; DeMichele et al, 2015; Finn et al, 2015, 2016; Cristofanilli et al, 2016; Hamilton & Infante, 2016; Sherr et al, 2016), PD0332991 combined with endocrine treatment substantially improved progression-free survival compared to endocrine…”
BackgroundMethodCyclin-dependent kinase (CDK) inhibitors in solid tumors: a review of clinical trials
Panagiotou, Ε., Gomatou, G., Trontzas, I. P., Syrigos, N. K., & Kotteas, E. A. (2021) · Clinical & Translational Oncology · doi:10.1007/s12094-021-02688-5 · Cited by 81
U.S. FDA Drug Approvals for Breast Cancer: A Decade in Review
Arora, S., Narayan, P., Osgood, C. L., Wedam, S. B., Prowell, T. M., Gao, J. J., Shah, M., Krol, D., Wahby, S., Royce, M., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2600 · Cited by 82
CDK4/6 inhibition as maintenance and combination therapy for high grade serous ovarian cancer
Iyengar, M., O’Hayer, P., Cole, A., Sebastian, T., Yang, K., Coffman, L., & Buckanovich, R. J. (2018) · Oncotarget · doi:10.18632/oncotarget.24585 · Cited by 75
Overcoming endocrine resistance in metastatic hormone receptor-positive breast cancer
D'souza, A., SPICER, D. V., & Lu, J. M. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0620-6 · Cited by 78
“PALOMA-2 was a phase III study of palbociclib and letrozole as first-line therapy for postmenopausal women with estrogen-receptor (ER)-positive, HER2-negative advanced breast cancer [15].”
BackgroundSayed, R. E., Jamal, L. E., Iskandarani, S. E., Kort, J., Salam, M. A., & Assi, H. I. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00510 · Cited by 82
“(86) Palbociclib + letrozole 1 444 62 0 100 100 100 48 56.”
BackgroundThe role of chemotherapy in treatment of advanced breast cancer: an overview for clinical practice
Claessens, A. K. M., Ibragimova, K. I. E., Geurts, S. M. E., Bos, M. E. M. M., Erdkamp, F., & Tjan‐Heijnen, V. C. G. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.102988 · Cited by 83
Metadata
- Authors
- Finn, R. S., Martin, M., Rugo, H. S., Jones, S., Im, S.-A., Gelmon, K., Harbeck, N., Lipatov, O. N., Walshe, J. M., Moulder, S., Gauthier, E., Lu, D. R., Randolph, S., Diéras, V., & Slamon, D. J.
- Affiliations
- Universidad Complutense de Madrid (ES)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-11-17
- Volume
- 375
- Issue
- 20
- Pages
- 1925-1936
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2552099557
- Cited by
- 3,007
- References
- 12
- Citations by year
- 2026: 278 · 2025: 346 · 2024: 349 · 2023: 343 · 2022: 310 · 2021: 363 · 2020: 299 · 2019: 260 · 2018: 284 · 2017: 157 · 2016: 9
- FWCI
- 210.30
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Seoul National University Open Repository (Seoul National University) (submittedVersion)
- Funders
- Health Research Board (ICORG-2016-1)
- Topics
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Keywords
- palbociclib, letrozole, advanced breast cancer, estrogen receptor-positive breast cancer, HER2-negative breast cancer, CDK4/6 inhibitors, progression-free survival, postmenopausal women, neutropenia, febrile neutropenia, overall survival, first-line therapy, drug safety and tolerability, patient-reported outcomes, pharmacokinetics, objective response rate
- MeSH terms
- Letrozole, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Double-Blind Method, Female, Humans, Middle Aged, Neutropenia, Nitriles, Piperazines, Pyridines, Receptors, Estrogen, Triazoles, Postmenopause, Disease-Free Survival, Cyclin-Dependent Kinases, Protein Kinase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.